Patient Information
Immune Diseases
Immunoglobulin Replacement Therapy in Primary Immunodeficiencies | SYSTEMIC LUPUS ERYTHEMATOSIS (SLE) |
|
|
|
Lupus is a disease of the immune system, which affects more than 17,000 Australians. Symptoms can be vague and vary from person to person, and consequently diagnosis can be difficult. However, once diagnosed, a combination of prescribed treatment and lifestyle adjustments enables most people with lupus to enjoy an almost normal life. What is lupus?The main role of the immune system is to fight foreign invaders such as bacteria, moulds and viruses. In autoimmune diseases the immune system produces antibodies that attack the body's own healthy tissue. Lupus is an autoimmune disease, and the antibodies produced by the immune system in lupus cause inflammation, tissue damage and pain. Who is affected by lupus?Lupus is most common in women (90%) and the majority develop the condition between 15 and 45 years. When lupus occurs in children it is usually diagnosed during puberty. There are two main types of lupusThere are two main types of lupus, which differ significantly in the type and severity of symptoms:
Other milder forms of lupus sometimes occur. In subacute cutaneous lupus the main symptoms are skin rashes, sun sensitivity and joint aches. Drug induced lupus is usually a transient form that develops as a reaction to certain medications and clears up when the medications are ceased. The cause of lupus is unknownAn interplay of genetic and environmental factors contribute to the formation of the antibodies that lead to lupus. SLE is characterised by flare ups and remissions. Some of the possible triggers of disease flare ups include hormones, certain medications and chemicals, viral and bacterial infections, exposure to UV light, dietary factors, stress and pregnancy. Lupus symptoms may be vague, variable and unpredictableLupus can cause many symptoms, including joint pain or swelling (seen in 50% of people with lupus), skin rashes that get worse with sun exposure (20% of people with lupus), fever, loss of appetite and weight loss. Fatigue, weakness and lethargy affects 10% of people with lupus and may be severe. Most people with lupus will never experience all the symptoms and no two individuals seem to experience identical symptoms. A subset of people with lupus are at increased risk of blood clots and recurrent pregnancy loss. The course of lupus is usually unpredictableFor some people, symptoms will subside after treatment of the initial acute attack. For others, periods of improvement (remission) are punctuated by brief flares of disease. Early diagnosis is importantThe diagnosis of lupus is usually suspected on the basis of clinical symptoms and signs and confirmed by laboratory tests. Blood tests will usually include an Anti Nuclear Antibody (ANA) test, which measures antibodies to self tissues. Whilst this is a good screening test, not all people with SLE have a positive ANA result and many people with a positive ANA do not have SLE. For example, close relatives of SLE patients may have a positive ANA without developing SLE themselves. Additional blood tests are necessary to confirm the diagnosis and to monitor the activity of SLE. Effective treatments are available for lupusThe aims of treatment for lupus are to reduce inflammation in tissues and to improve quality of life. Treatment must be individualised, taking account of the severity of the disease. There are five main groups of drugs that are used to treat lupus:
Diagnosis, treatment and lifestyle changes are importantThe outlook for most people with lupus is good. Early detection, effective treatment and some lifestyle adjustments enable most people with lupus to feel well and live normal lives. It is only a small minority of people who find the condition substantially reduces their quality of life. Lupus and pregnancyWomen with lupus should talk to their doctor before considering pregnancy. They should be made aware of any potential risk for themselves and the baby. It is preferable for lupus to be in remission, as this reduces the risk of a disease flare occurring during pregnancy. Lupus flares occurring during pregnancy are usually mild and occur in the first three months (trimester). In the first few weeks after birth new mothers may experience lupus flares but this can be controlled with corticosteroids. It is important to discuss therapy options with your doctor to ensure that any current medication taken will not adversely affect the pregnancy. Women should have no difficulty becoming pregnant as lupus does not usually lower fertility, but a small proportion of women will suffer recurrent miscarriage. Some tips to help people with lupus to lead normal livesThe following tips may assist people with lupus to lead normal lives:
There are currently no cures for lupus, but there are effective medications that will bring the disease under control, and often permanently. As you grow older, it is likely that the disease will improve. There are a number of organisations which provide support and information to people with lupus and their families, as well as promoting understanding and awareness of the condition in the community. They can also organise funding for further research into lupus and its management. A list of these organisations is available on the ASCIA website www.allergy.org.au/content/view/140/67/ © ASCIA 2010 The Australasian Society of Clinical Immunology and Allergy (ASCIA) is the peak professional body of Clinical Immunologists and Allergists in Australia and New Zealand. Website: www.allergy.org.au Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Postal address: PO Box 450 Balgowlah NSW 2093 Australia DisclaimerThis document has been developed and peer reviewed by ASCIA members and is based on expert opinion and the available published literature at the time of review. Information contained in this document is not intended to replace medical advice and any questions regarding a medical diagnosis or treatment should be directed to a medical practitioner. The development of this document is not funded by any commercial sources and is not influenced by commercial organisations. Content last updated January 2010 |
|
| Last Updated ( Monday, 07 June 2010 ) |
| < Prev | Next > |
|---|
ASCIA MENU
Ascia Education Resources
| Patient Support Information |
| About AER |
| Patient Information |
| Health Professional Information |



